The Centers for Medicare & Medicaid Services Makes Preliminary Recommendation to Establish New HCPCS Billing Code Dedicated to Arch Therapeutics’ AC5® Advanced Wound System
December 05, 2022 06:50 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical...
Key Opinion Leaders Presented Arch Therapeutics’ AC5® Advanced Wound System at 2022 Symposium on Advanced Wound Care (SAWC) Fall
October 18, 2022 06:50 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical...
Arch Therapeutics’ AC5® Advanced Wound System to be Presented with Honors at 2022 Symposium on Advanced Wound Care (SAWC) Fall
October 11, 2022 06:45 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical...
Arch Therapeutics Announces First Shipments of AC5® Advanced Wound System Under New Reimbursement Support Program
September 23, 2022 06:50 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Sept. 23, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical...
Arch Therapeutics Accepted to Present AC5® Advanced Wound System During Innovation Spotlight at 2022 Symposium on Advanced Wound Care (SAWC)
September 20, 2022 06:50 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical...
Arch Therapeutics Announces Intent to Uplist from OTC to a National Exchange
September 16, 2022 06:50 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical...
Arch Therapeutics Launches Multi-Site Clinical Study for AC5® Advanced Wound System
September 07, 2022 06:50 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical...
Arch Therapeutics Submits Application to Centers for Medicare and Medicaid Services for AC5® Advanced Wound System
September 01, 2022 06:50 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical...
Arch Therapeutics Raises Approximately $3.5 Million in Convertible Note Financing
July 07, 2022 07:50 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., July 07, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical...
Arch Therapeutics Provides Update on Reimbursement Strategy in Additional Selling Channel
June 22, 2022 07:50 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., June 22, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical...